Lamotrigine monotherapy for paroxysmal kinesigenic dyskinesia in children

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-15006294

Enrollment

Unknown

Registered

2015-04-22

Start date

2015-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

paroxysmal kinesigenic dyskinesia

Interventions

LTG group:treatment of LTG

Eligibility

Sex/Gender

All

Age

2 Years to 16 Years

Inclusion criteria

Inclusion criteria: 1. All the patients were diagnosed with PKD according to the clinical diagnostic criteria of Bruno in 2004; 2. Lamotrigine monotherapy for treatment in our study; 3. have good obedience and follow up; 4. All the patients had a normal video-EEG and Brain CT or MRI scans.

Exclusion criteria

Exclusion criteria: 1. With severe organic diseases such as blood disease,like liver or kidney dysfunction; 2. Suffering from any Progressive diseases such as cancer; 3. Suffering from any organic brain or central nervous system diseases; 4. Suffering any disease may cause secondery PKD, like tuberous sclerosis.

Design outcomes

Primary

Measure	Time frame
frequency of attack;	—

Countries

China

Contacts

Public ContactZhongdong Lin

wzlzhd@163.com+86 13957713578

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026